Cytek Biosciences, Inc. Chief Technology Officer and Director Yan Ming filed a Form 4 on November 20, 2026, reporting four restricted stock unit vesting events and related tax-withholding share disposals that occurred on November 18, 2026.

Key Highlights

  • Four RSU tranches vested: Yan Ming acquired 7,363, 5,525, 6,162, and 14,220 shares of Common Stock through RSU conversions on November 18, 2026, totaling 33,270 shares acquired via code "M" transactions.
  • Tax withholding disposals: The company withheld 1,793, 1,346, 1,501, and 3,463 shares, respectively, at $5.92 per share to satisfy tax obligations arising from the RSU vestings, totaling 8,103 shares disposed under code "F."
  • Remaining beneficial ownership: Following all reported transactions, Yan Ming directly owned 4,847,037 shares of Common Stock.
  • Remaining RSUs: After the four vesting events, Yan Ming held 9,826, 29,470, 57,526, and 189,615 RSUs, respectively, across the four award tranches.
  • Roles reported: Yan Ming is identified in the filing as both a Director and Chief Technology Officer of Cytek Biosciences, Inc. (NASDAQ:CTKB).

Yan Ming RSU Vesting and Tax-Withholding Transactions at Cytek Biosciences

According to the filing, Yan Ming, who serves as Chief Technology Officer and Director of Cytek Biosciences, Inc. (NASDAQ:CTKB), reported four separate RSU vesting events on November 18, 2026. Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock, as the filing states. The four tranches converted were 7,363 shares, 5,525 shares, 6,162 shares, and 14,220 shares, all recorded under transaction code "M" (conversion of derivative security).

Concurrent with each vesting, the filing discloses that shares were withheld by and surrendered to the issuer to satisfy tax withholding obligations. The shares withheld were 1,793, 1,346, 1,501, and 3,463, respectively, all at a price of $5.92 per share and recorded under transaction code "F." The filing describes these disposals as representing "the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award."

The four RSU awards carry staggered vesting schedules over four years each, beginning in 2023, 2024, 2025, and 2026, respectively, with portions vesting on specific dates in May, August, November, and March of each applicable year. After all reported transactions, Yan Ming's direct beneficial ownership of Common Stock stood at 4,847,037 shares, according to the filing. The form was signed by Wenbin Jiang as Attorney-in-Fact and filed on November 20, 2026.

What Was Disclosed

The filing reports four RSU vesting events totaling 33,270 shares acquired and 8,103 shares withheld at $5.92 for tax purposes by Cytek Biosciences CTO and Director Yan Ming on November 18, 2026, with resulting direct ownership of 4,847,037 shares of Common Stock.